McEwen Inc Form 4 Filings

McEwen Inc. director Richard W. Brissenden reported an open-market sale and an option exercise involving the company’s common stock. On June 29, 2026, he sold 3,275 shares at a weighted average price of $18.1289 per share, in multiple trades between $18.07 and $18.19. He also exercised stock options to acquire 8,333 common shares at $7.10 per share, fully eliminating that option position. After these transactions, he directly holds 18,022 common shares.

McEwen Inc. VP Finance Jeffrey Chan exercised restricted stock units into common shares as part of equity compensation. On June 28, 2026, he acquired 588 shares of common stock from one vested RSU award and 248 shares from another, both at a stated price of $0.00 per share.

The underlying RSU grants had vested as to 1,266 units and 533 units, respectively, with 678 units and 285 units from those grants settled for cash instead of shares. Following these transactions, Chan directly held 4,775 shares of McEwen Inc. common stock, reflecting routine equity award settlement rather than any open‑market trading.

McEwen Inc. director Ian J. Ball exercised restricted stock units that vested on June 29, 2026, receiving 160 shares of common stock and cash for 150 vested units. Following the transaction, he directly holds 320 shares of common stock and 310 remaining restricted stock units that are scheduled to vest on December 20, 2026.

McEwen Inc. General Counsel Carmen L. Diges reported routine compensation-related transactions involving restricted stock units (RSUs). On June 28–29, 2026, she exercised a total of 7,053 RSUs linked to common stock, with each unit converting at an exercise price of $0.00 per unit.

According to the disclosures, all vested RSUs from these grants were settled for cash rather than delivering common shares. Portions of several award grants vested on June 28 and June 29, 2026, while 760 RSUs from more recent grants remain scheduled to vest in installments through December 20, 2026 and June 29, 2027.

McEwen Inc. Chief Operating Officer William M. Shaver reported the vesting of restricted stock units that were settled in common shares. On June 28–29, 2026, he exercised derivative awards to acquire a total of 21,886 shares of common stock at a stated price of $0.00 per share.

The vested amounts came from several prior RSU grants, including 2,100 and 866 shares that vested on June 28, 2026, and 11,740 and 5,700 shares that vested on June 29, 2026. Following these transactions, he directly owns 171,086 shares of McEwen common stock and retains additional RSUs scheduled to vest in December 2026 and June 2027.

McEwen Inc. VP Corporate Development Stephan Michael Spears exercised restricted stock units that were settled entirely in cash rather than stock. On June 28, 2026, he exercised 1,700 restricted stock units tied to common shares, consisting of 1,200 units from an August 11, 2025 grant and 500 units from a September 8, 2025 grant. The award terms allow settlement in shares or their cash value at the discretion of the Compensation, Nominating & Corporate Governance Committee, and in this case all vested units were paid out in cash, with no open-market share purchases or sales reported.

McEwen Inc.’s Chief Financial Officer Perry Ing reported a series of compensation-related equity transactions. On June 28 and June 29, 2026, he exercised derivative awards, resulting in the acquisition of 10,366 shares of common stock, and his direct holdings rose to 48,094 shares of common stock.

The transactions reflect vesting and settlement of multiple restricted stock unit (RSU) grants, some of which were settled in cash rather than shares as described in the award terms. Following these events, 1,260 RSUs from a March 19, 2026 grant and 2,330 RSUs from a November 10, 2025 grant remain outstanding and are scheduled to vest in installments through December 20, 2026 and June 29, 2027.

McEwen Inc. VP of Finance Jeffrey Chan reported a routine equity compensation event involving restricted stock units and common shares. On December 20, 2025, he acquired 248 shares of common stock through the exercise of a derivative award, bringing his direct common stock holdings to 3,939 shares.

On the same date, 533 restricted stock units vested, each representing the right to one share of common stock or its cash value. According to the award terms, 285 of these units settled in cash, and the remaining units are scheduled to vest on June 28, 2026, under the oversight of the company’s Compensation, Nominating & Corporate Governance Committee.

McEwen Inc. director Stephen Douglas Kaszas bought 1,000 shares of McEwen common stock in an open-market transaction. The shares were purchased at $18.36 per share, bringing his direct holdings to 1,621 shares after the trade. The U.S. dollar price reflects a conversion from C$25.56 per share using a Bank of Canada exchange rate of C$1.00 = US$0.7182 on June 5, 2026.

Shaver William M reported acquisition or exercise transactions in this Form 4 filing.

McEwen Inc. director and Chief Operating Officer William M. Shaver received equity-based compensation in the form of stock units. He was granted 4,440 restricted stock units, each representing a contingent right to one share of common stock or its cash value, vesting in three equal installments on June 29, 2026, December 20, 2026 and June 29, 2027. He was also awarded 479 deferred stock units, each representing a right to one share of common stock, which are fully vested and will be delivered when his continuous service on the Board ends, subject to his ability to elect a later delivery date.

Makori Michelle reported acquisition or exercise transactions in this Form 4 filing.

McEwen Inc. director Michelle Makori received a grant of 239 deferred stock units tied to common stock. The units were awarded at no cash cost and each unit represents one share of common stock. They are fully vested and will be delivered after Makori’s service on the Board ends, with an option to further defer delivery.

McEwen Inc.’s Chief Financial Officer Perry Ing received a grant of 1,890 restricted stock units. This Form 4 shows an award-type acquisition, not an open-market trade. Following the grant, Ing directly holds 1,890 restricted stock units.

Each restricted stock unit represents a contingent right to receive one share of McEwen’s common stock, or the cash value of a share, as determined under the award agreement by the Compensation, Nominating & Corporate Governance Committee. The units will vest in three approximately equal installments on June 29, 2026, December 20, 2026 and June 29, 2027.

Florek John Casimir reported acquisition or exercise transactions in this Form 4 filing.

McEwen Inc. director John Casimir Florek received a grant of 479 deferred stock units as board compensation. These units were awarded at no cash cost and increase his directly held deferred stock units to a total of 1,790.

Each deferred stock unit represents the right to receive one share of McEwen common stock. The units are fully vested but will be delivered only when Florek’s continuous service on the board ends, although he may elect to defer delivery beyond that termination date.

Diges Carmen L reported acquisition or exercise transactions in this Form 4 filing.

McEwen Inc. General Counsel Carmen L. Diges received an award of 1,140 restricted stock units (RSUs) tied to the company’s common stock. These RSUs were granted as compensation at no cost and bring her directly held RSU balance to 1,140 units.

Each RSU represents the right to receive one share of McEwen Inc. common stock, or its cash value, at the discretion of the board’s Compensation, Nominating & Corporate Governance Committee. The award vests in three equal installments on June 29, 2026, December 20, 2026, and June 29, 2027, aligning her incentives with longer-term company performance rather than reflecting an open‑market share purchase or sale.

Darveau-Garneau Nicolas reported acquisition or exercise transactions in this Form 4 filing.

McEwen Inc. director Nicolas Darveau-Garneau was granted 479 deferred stock units (DSUs). Each DSU represents one share of McEwen common stock. The units are fully vested and will be delivered when his continuous service on the Board ends, with an option to further defer delivery.

Asterbadi Dalia Nadine reported acquisition or exercise transactions in this Form 4 filing.

McEwen Inc. director Dalia Nadine Asterbadi received 479 Deferred Stock Units (DSUs), increasing her directly held DSUs to 1,790. Each DSU represents the right to receive one share of McEwen Inc. common stock.

The DSUs are fully vested and will be delivered when she leaves the Board of Directors, although she may elect to defer delivery beyond that termination date.

McEwen Inc. officer Carmen L. Diges, the company’s General Counsel and Corporate Secretary, reported the vesting and cash settlement of several restricted stock unit (RSU) awards on December 20, 2025.

RSUs granted on June 29, 2025 vested as to 3,370 units, and RSUs granted on November 10, 2025 vested as to 1,470 units, with all vested amounts settled for cash rather than shares. Additional RSUs granted on August 11, 2025 and September 8, 2025 had their second vesting events accelerated to December 20, 2025, resulting in 1,300 and 533 units vesting, respectively, also settled for cash.

The remaining RSUs from these grants are scheduled to vest on future dates in 2026, reflecting ongoing equity-based compensation for this executive.

McEwen Inc. director Ian J. Ball reported equity compensation activity involving the company’s common stock. On December 20, 2025, he acquired 160 shares of common stock through an exempt transaction coded “M,” leaving him with 160 common shares held directly after the transaction.

On the same date, 310 restricted stock units (RSUs) vested from an award originally granted on November 10, 2025. Each RSU represents a right to receive one share of common stock or its cash value, at the discretion of the Compensation, Nominating & Corporate Governance Committee. Of the 310 vested RSUs, 150 shares were settled in cash. The remaining RSUs from this grant are scheduled to vest in two equal installments on June 29, 2026 and December 20, 2026, and Ball reported 620 RSUs beneficially owned directly after the transaction.

McEwen Inc.'s VP Finance reported equity compensation activity involving restricted stock units and common shares. On December 20, 2025, the officer exercised restricted stock units (coded "M" for conversion) that delivered 588 and 275 shares of McEwen Inc. common stock in two transactions. After these transactions, the officer directly owned 3,691 and 3,966 common shares, respectively.

The filing also details two restricted stock unit awards that converted into common stock on December 20, 2025. One award covered 1,266 shares of common stock and another covered 533 shares, each at an exercise price of $0. The vesting schedules for both awards had previously been amended to accelerate a vesting event from December 28, 2025 to December 20, 2025, with a portion of the vested units settled in cash and the remaining units scheduled to vest on June 28, 2026.

McEwen Inc. Chief Financial Officer Perry Ing reported the vesting and settlement of several restricted stock unit (RSU) awards on December 20, 2025. Multiple RSU grants converted into shares of McEwen common stock through automatic transactions coded “M,” increasing his directly held stake over the course of the day to 46,594 shares of common stock.

The RSU awards were originally granted on June 29, 2025; November 10, 2025; August 11, 2025; and September 8, 2025. Portions of these awards vested on December 20, 2025, with some of the vested units settling in cash (including 2,537, 1,247, 999 and 428 units from the respective grants) and the remainder settling in shares. The filing notes that remaining unvested RSUs are scheduled to vest in 2026, and certain vesting dates were accelerated from late December 2025 to December 20, 2025.

McEwen Inc. officer reports accelerated RSU vesting and cash settlement. A company officer, listed as VP Corporate Development, reported activity in restricted stock units tied to McEwen Inc. common stock. One RSU grant made on August 11, 2025 had its vesting schedule amended so the second vesting event moved from December 28, 2025 to December 20, 2025, causing 1,200 units to vest and be settled entirely in cash on that date, with remaining units scheduled to vest on June 28, 2026. A second RSU grant made on September 8, 2025 was amended in the same way, leading to 500 units vesting and being settled for cash on December 20, 2025, with the balance also scheduled to vest on June 28, 2026. Each RSU represents a contingent right to receive one share of common stock or its cash value, at the discretion of the board committee.

McEwen Inc. director and Chief Operating Officer William M. Shaver reported the vesting of several restricted stock unit awards and related acquisitions of common shares. On December 20, 2025, restricted stock units granted on June 29, 2025 vested as to 11,740 shares, those granted on November 10, 2025 vested as to 5,700 shares, and earlier grants from August 11, 2025 and September 8, 2025 vested as to 2,100 and 867 shares, respectively. Each unit converts into one share of common stock or its cash value at the discretion of the company’s Compensation, Nominating & Corporate Governance Committee.

Following these transactions, Shaver directly owned 149,200 shares of McEwen Inc. common stock. The remaining portions of these awards are scheduled to vest on specified future dates in 2026 according to each grant’s vesting schedule.

McEwen Inc. (MUX) reported insider equity activity by its VP Corporate Development. On November 10, 2025, the officer acquired a total of 790 shares of common stock through conversions of restricted stock units, increasing his directly held stake to 4,604 shares.

These transactions came from vesting of two restricted stock unit awards originally granted on August 11, 2025 and September 8, 2025. For the first award, 1,200 units vested on November 10, 2025, with 642 shares settling in cash and the rest in stock, and the remaining units vest in two equal installments on December 28, 2025 and June 28, 2026. For the second award, 500 units vested on November 10, 2025, with 268 shares settling in cash, and the balance vesting on the same two future dates.

McEwen Inc. (MUX) officer Stephan Michael Spears, VP Corporate Development, reported an option exercise and share sale involving the company’s common stock. On 09/19/2025, he exercised 12,600 stock options at an exercise price of $1.25 per share and acquired the same number of common shares. That same day, he disposed of 12,600 common shares in an open-market sale at a weighted average price of $14.3477 per share, with individual trades ranging from $13.71 to $14.65. Following these transactions, Spears beneficially owned 3,814 shares of McEwen common stock directly. The filing notes that the reported option was granted in 2020, vested in three equal annual installments beginning on September 29, 2021, and was nearing its September 28, 2025 expiration date, with figures adjusted for McEwen’s 10-for-1 reverse stock split effective July 28, 2022.

McEwen Inc. (MUX) Form 4: Chief Operating Officer and Director William M. Shaver reported RSU-related transactions on November 10, 2025. Two tranches of restricted stock units vested and were settled into common stock: 2,100 shares and 867 shares via code M. Following these, his directly held common stock was 128,793 shares.

On the same date, he received a new award of 17,100 restricted stock units at $0 price. Footnotes detail prior grants on August 11, 2025 and September 8, 2025, with remaining RSU vesting scheduled in equal installments on December 28, 2025 and June 28, 2026; the new 17,100-unit award vests in three equal installments on December 20, 2025, June 29, 2026, and December 20, 2026.

McEwen Inc. (MUX) filed a Form 4 disclosing CFO Perry Ing’s equity activity. On November 10, 2025, restricted stock units (RSUs) vested and partially settled in cash, resulting in stock deliveries of 867 shares and 372 shares.

The 1,868 RSUs granted on August 11, 2025 vested as to 1,868 shares on November 10, 2025, of which 1,001 shares settled for cash. The 800 RSUs granted on September 8, 2025 vested as to 800 shares on November 10, 2025, of which 428 shares settled for cash. Following these transactions, common shares beneficially owned were 42,069 (direct).

Ing also received a new award of 6,990 RSUs on November 10, 2025. These will vest in three equal installments on December 20, 2025, June 29, 2026 and December 20, 2026. Remaining portions of the August 11 and September 8 RSU grants are scheduled to vest in equal installments on December 28, 2025 and June 28, 2026.

McEwen Inc. (MUX) filed a Form 4 disclosing a director transaction. On 11/10/2025, the reporting person acquired 585 deferred stock units (DSUs) at $0. Each DSU represents one share of common stock and is fully vested. Delivery occurs upon the director’s termination of continuous service from the Board, with an option to defer delivery. Following the transaction, the director beneficially owned 1,311 derivative securities.

McEwen Inc. (MUX) reported insider equity changes by its VP - Finance. On November 10, 2025, restricted stock units (RSUs) vested from two grants: 1,268 RSUs from an August 11, 2025 award (with 680 shares settling for cash) and 534 RSUs from a September 8, 2025 award (with 286 shares settling for cash).

Table I shows code M conversions resulting in acquisitions of common stock: 588 shares and 248 shares. The remaining RSUs from both grants are scheduled to vest in two equal installments on December 28, 2025 and June 28, 2026.

McEwen Inc. (MUX) reported a director equity grant on 11/10/2025. The filing shows an award of 50,000 stock options at an exercise price of $17.09, expiring on 11/10/2030. These options vest in three equal annual installments beginning on November 10, 2026.

The director also received 930 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock, or the cash value per the award agreement at the Compensation, Nominating & Corporate Governance Committee’s discretion. The RSUs vest in three installments on December 20, 2025, June 29, 2026, and December 20, 2026.

McEwen Inc. (MUX) director John Casimir Florek reported acquiring 585 deferred stock units on 11/10/2025 at a price of $0.

Each deferred stock unit represents the right to receive one share of McEwen common stock. The units are fully vested and will be delivered upon the director’s termination of continuous service from the Board, subject to the director’s deferral election. Following the transaction, Florek beneficially owned 1,311 derivative securities directly.

McEwen Inc. (MUX) reported insider activity by its General Counsel/Corporate Secretary, Carmen L. Diges, on a Form 4. On November 10, 2025, restricted stock units (RSUs) vested and converted into common stock, and a new RSU grant was recorded.

Two prior RSU awards vested: 1,300 RSUs vested, with 628 shares settled for cash; and 534 RSUs vested, with 258 shares settled for cash. These correspond to 672 and 276 shares, respectively, acquired via code M. The amended vesting schedules state the remaining shares from these awards vest in two equal installments on December 28, 2025 and June 28, 2026.

A new award of 4,410 RSUs was reported, vesting in three equal installments on December 20, 2025, June 29, 2026, and December 20, 2026. Following the transactions, direct beneficial ownership stood at 27,044 common shares. Indirect holdings were listed as 5,000 shares through Diges Professional Corporation and 7,500 shares through Pleasant Memories Enterprises Inc.

McEwen Inc. (MUX) director equity update: A company director reported an acquisition of 585 deferred stock units on 11/10/2025, as shown on a Form 4. Each deferred stock unit represents the right to receive one share of common stock.

The deferred stock units are fully vested and will be delivered upon the director’s termination of continuous service from the Board, with an option to defer delivery further. Following the transaction, the director beneficially owned 1,311 derivative securities, held directly.

McEwen Inc. reporting person Carmen L. Diges amended a Form 4 to correct option/share counts after a 10-for-1 reverse split. The filing shows on 09/19/2025 Ms. Diges exercised 21,000 stock options with a $1.25 exercise price and simultaneously sold 21,000 common shares for a weighted average price of $14.3446. Following these transactions she beneficially owns 26,096 shares of McEwen Inc. The amendment corrects the number of options and underlying shares to reflect the reverse split effective July 28, 2022.

Robert Ross McEwen, Chairman and CEO of McEwen Inc. (MUX), filed an amended Form 4 reporting matched option exercise and stock sale transactions on 09/19/2025. He exercised a stock option with a $1.25 exercise price to acquire 50,000 shares and sold 50,000 shares at a weighted-average price of $14.3467, resulting in 50,000 shares beneficially owned after the transactions. The filing corrects prior reporting to reflect the issuer's 10-for-1 reverse split effective 07/28/2022. The option vested in three equal annual installments beginning 09/29/2021. The amendment is signed 09/29/2025.

Insider transactions by Richard W. Brissenden at McEwen Inc. (MUX) show multiple option exercises and open-market sales on 09/22/2025. Mr. Brissenden exercised a $1.25 option for 7,500 shares that was nearing its 09/28/2025 expiration and a $7.10 option for 8,334 shares (vesting schedule noted). He sold 6,428 shares at a weighted average price of $14.8885 and 4,775 shares at a weighted average price of $14.8834. After these trades he beneficially owned 12,964 shares and held 8,333 exercisable shares from the $7.10 option.

Jeffrey Chan, Vice President - Finance at McEwen Inc. (MUX), reported transactions on 09/22/2025. The filing shows he acquired a stock option covering 13,333 shares with an exercise price of $7.10 and an exercisable schedule that vests in three equal annual installments beginning 06/29/2024, and that after the option his direct beneficial ownership of the option equals 13,333 underlying shares. On the same date he sold 13,333 common shares in multiple transactions at a weighted-average price of $14.8898 (individual sale prices ranged $14.59–$15.103). Following the reported trades his direct common stock holdings are shown as 2,267 shares and he holds options underlying 13,333 shares (6,667 shown exercisable now). The filing is a routine Section 16 disclosure of insider exercises and sales.

Carmen L. Diges, General Counsel and Corporate Secretary of McEwen Inc. (MUX), exercised 210,000 stock options at a $1.25 exercise price and simultaneously sold 21,000 shares at a weighted-average price of $14.3446 on 09/19/2025. The option exercise increased reported direct beneficial ownership to 236,096 shares before the sale and to 215,096 shares after the sale. The exercised options were part of a grant that vested in three equal annual installments beginning 09/29/2021 and were nearing their 09/28/2025 expiration.

Robert R. McEwen, Chairman and CEO of McEwen Inc. (MUX), exercised stock options and reported related open-market sales. He exercised an option to acquire 500,000 common shares at an exercise price of $1.25 per share, and immediately sold 50,000 shares at a weighted-average price of $14.3467. After these transactions, Mr. McEwen directly beneficially owned 500,000 shares; an additional 8,236,647 shares are held indirectly by a corporation wholly owned by him (2190303 Ontario Inc.), and 35,280 shares are held indirectly by his spouse. The filing notes the option vested in three equal annual installments beginning September 29, 2021, and that the option was nearing its September 28 expiration.

Robert R. McEwen, Chairman and CEO of McEwen Inc. (MUX), amended a Form 4 to report acquisitions tied to a loan arrangement. On 05/06/2025, 2190303 Ontario Inc., a company wholly owned by Mr. McEwen, received 53,160 common shares as partial consideration for extending a loan to McEwen Copper Inc., an entity in which McEwen Inc. holds an indirect 46.6% equity interest. The shares were valued at $7.5245 each using the NYSE volume-weighted average price from 02/18/2025 to 03/31/2025. The filing also notes 35,280 shares held indirectly by spouse. The amendment clarifies the transaction is exempt from Section 16(b) under Rule 16b-3(d) and that the loan was made to the equity investee, not McEwen Inc.